Merck ’s KEYTRUDA® (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1
Dateline City:
KENILWORTH, N.J. Approval Based on Trial Results Demonstrating Superior Overall Survival Compared to Chemotherapy in Previously-Treated PatientsKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the European Commission (EC) has approved KEYTRUDA®
(pembrolizumab), the company ’s anti-PD-1 therapy, at a dose of 2 mg/kg
every three weeks, for patients with locally advanced or metastatic
non-small cell lung cancer (NSCLC) in patients whose tumors express
PD-L1 and who have received at least one prior chemotherapy regimen.Language:
EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSEread more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News #Merck #MRK $MRK cancer Keytruda MSD Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Merck | Non-Small Cell Lung Cancer | Pharmaceuticals